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 ORIGINAL ARTICLE 
Acta Oncologica, 2010; 49: 1033–1039 Prediction of residual metabolic activity after treatment 
in NSCLC patients  EMMANUEL RIOS  VELAZQUEZ ,  HUGO J. W. L.  AERTS, CARY  OBERIJE , 
 DIRK DE  RUYSSCHER  &  PHILIPPE  LAMBIN 
 Department of Radiation Oncology (MAASTRO), GROW- School for Oncology and Developmental Biology, 
Maastricht University Medical Center (MUMC  ), Maastricht, The Netherlands  Abstract 
 Purpose . Metabolic response assessment is often used as a surrogate of local failure and survival. Early identifi cation of 
patients with residual metabolic activity is essential as this enables selection of patients who could potentially benefi t 
from additional therapy. We report on the development of a pre-treatment prediction model for metabolic response using 
patient, tumor and treatment factors.  Methods . One hundred and one patients with inoperable NSCLC (stage I-IV), treated 
with 3D conformal radical (chemo)-radiotherapy were retrospectively included in this study. All patients received a 
pre and post-radiotherapy fl uorodeoxyglucose positron emission tomography-computed tomography FDG-PET-CT scan. 
The electronic medical record system and the medical patient charts were reviewed to obtain demographic, clinical, 
tumor and treatment data. Primary outcome measure was examined using a metabolic response assessment on a post-
radiotherapy FDG-PET-CT scan. Radiotherapy was delivered in fractions of 1.8 Gy, twice a day, with a median prescribed 
dose of 60 Gy.  Results . Overall survival was worse in patients with residual metabolic active areas compared with the 
patients with a complete metabolic response (p  0.0001). In univariate analysis, three variables were signifi cantly associ-
ated with residual disease: larger primary gross tumor volume (GTV primary , p  0.002), higher pre-treatment maximum 
standardized uptake value (SUV max , p  0.0005) in the primary tumor and shorter overall treatment time (OTT, p  0.046). 
A multivariate model including GTV primary , SUV max , equivalent radiation dose at 2 Gy corrected for time (EQD 2, T ) 
and OTT yielded an area under the curve assessed by the leave-one-out cross validation of 0.71 (95% CI, 0.65 – 0.76). 
 Conclusion . Our results confi rmed the validity of metabolic response assessment as a surrogate of survival. We developed 
a multivariate model that is able to identify patients at risk of residual disease. These patients may benefi t from an indi-
vidualized and more adequate therapeutic approach, thereby improving local control and survival.  Lung cancer is an important cause of cancer-related 
deaths worldwide [1]. In 2008, lung cancer was the 
most common cause of death from cancer with an 
estimate of 342 000 deaths in Europe [1]. Non-small 
cell lung cancer (NSCLC) accounts for at least 80% 
of all lung cancer cases [2]. The majority of these 
NSCLC patients present advanced-stage disease (stage 
III and IV), which are considered inoperable [3]. For 
these patients, the combination of radiotherapy and 
chemotherapy shows improved treatment outcome 
[4,5], however local tumor failure is still observed in 
approximately 70% of patients [6]. Therefore early 
identifi cation of patients with a high risk of local 
treatment failure is important, as these patients may   Correspondence: Emmanuel Rios Velazquez, Department of Radiation Oncolo
Netherlands and Maastro Clinic, Dr. Tanslaan 12, 6229 ET Maastricht, The Ne
rios@maastro.nl
 (Received 19 May 2010; accepted 28 May 2010) 
ISSN 0284-186X print/ISSN 1651-226X online © 2010 Informa Healthcare
DOI: 10.3109/0284186X.2010.498441potentially benefi t from additional therapy. One 
method of investigating local treatment failure, is 
assessing metabolic response within the primary 
tumor after treatment with  18 Fluorodeoxyglucose 
(FDG) positron emission tomography (PET) imag-
ing [7]. Several studies indicated that patients with 
metabolically active residual masses after treatment 
have a poorer prognosis compared to patients with-
out residual metabolic activity [8,9]. Although, other 
studies have shown that FDG uptake before treat-
ment is prognostic for residual metabolic activity 
within the tumor [9 – 11], other pre-treatment clinical 
factors were not investigated for their prognostic 
capability. Therefore, we hypothesize that also other gy, (MAASTRO), Maastricht University Medical Center, Maastricht, The 
therlands. Tel:   31 43 3882909. Fax:   31 43 3884540. E-mail: emmanuel.
1034  E. R. Velazquez et al. pre-treatment factors, including demographic, tumor 
and treatment characteristics, can have prognostic 
value for predicting metabolic response after treat-
ment. In the present study we examined the associa-
tion between commonly used prognostic factors in 
NSCLC patients and metabolic response after treat-
ment in a univariate and multivariate analysis. 
 Materials and methods 
 Patient characteristics 
 The electronic medical record system and the medi-
cal patient charts were retrospectively reviewed to 
obtain demographic, clinical, tumor and treatment 
data. One hundred and one patients (40 women and 
61 men) with inoperable non-small cell lung cancer 
(NSCLC), stage I-IV, were included in this study. 
Their age ranged from 43 to 86 years (mean: 65.6 
years). All patients were treated with curative intent 
at MAASTRO Clinic with sequential chemo-
radiotherapy (82 patients) or with radical radiotherapy 
alone (19 patients) between December 2004 and 
September 2007. All patients received a pre and post-
treatment FDG-PET-CT scan. For patients receiving 
sequential chemo-radiotherapy the pre-treatment 
scan was performed after chemotherapy. The average 
time interval between the last radiotherapy and 
the second FDG-PET-CT scan was 99 days (range: 
49 – 184 days). No treatment was given between the 
end of radiotherapy and the post-treatment scan. 
 FDG-PET-CT Imaging 
 Pre and post-treatment FDG-PET-CT scans were 
performed using a Siemens Biograph (Siemens, 
Knoxville, TN). All patients were instructed to fast 
at least six hours before the intravenous admini-
stration of FDG (Tyco Health Care, Amsterdam, 
The Netherlands), followed by physiologic saline 
(10 ml). The total injected activity of FDG was depen-
dent on the patient weight: (weight ∗ 4)   20 Mbq. 
After a period of 45 minutes, during which the patient 
was encouraged to rest, PET and CT imaging were 
performed [12]. 
 Treatment characteristics 
 The radiotherapy treatment was delivered in fractions 
of 1.8 Gy, twice a day, with a mean lung dose (MLD) 
restricted to 19 Gy and a maximal allowed total tumor 
dose (TTD) of 79.2 Gy [12]. Patients with stage III 
disease, who where physically fi t enough received 
sequential chemo-radiotherapy, consisting of three 
courses of gemcitabine in combination with cisplatin 
or carboplatin, followed by radiotherapy as described 
for stage I/II. No concurrent chemo-radiotherapy was given. The biologic equivalent dose was used as indi-
cation of the intensity of chest RT delivered to the 
tumor and was calculated using the quadratic model 
[13] and corrected for overall treatment time. 
 Metabolic response 
 Metabolic response was assessed for all patients with 
a FGD-PET-CT scan after treatment. Residual dis-
ease was defi ned as residual metabolic activity within 
the primary tumor, i.e. areas with FDG uptake higher 
than in the aortic arch (SUV   SUV AORTA ) [7,8]. If 
there was no activity within the tumor, patients were 
defi ned as with a complete metabolic response [10]. 
Survival data were obtained by reviewing the Dutch 
Communal Data register. Survival time was defi ned 
as the date from the start of radiotherapy until the 
date of death or last follow-up. Survival status could 
not be retrieved for one patient. 
 Statistical analysis 
 All data are expressed as means   SD. Because the 
distribution of the continuous variables was rather 
skewed, the Mann-Whitney U test was used to deter-
mine statistical differences between the patients with 
and without residual disease. For categorical vari-
ables the  χ 2 test was used. Differences were consid-
ered to be signifi cant when the p-value was lower 
than 0.05. The area under the curve (AUC) of the 
receiver operating characteristic (ROC), a plot of the 
true positive rate (correctly classifi ed positive sam-
ples) and false positive rate (incorrectly classifi ed 
negative samples) was used to analyze the association 
between the variables and residual disease in uni-
variate analysis using a proximal-support vector 
machine (p-SVM) [14]. A p-SVM was also used to 
build a multivariate prediction model, using meta-
bolic residual disease as outcome measure. Combi-
natorial feature selection was performed to obtain an 
optimal subset of features. The set of variables with 
the highest AUC of the ROC curve was included in 
the multivariate predictive model. The Kaplan-Meier 
method was used to estimate survival probabilities 
and statistical differences were assessed using the 
log-rank test. Data were considered right-censored 
if patients were alive at the time of last follow-up. 
All the analyses were performed in Matlab 2008b 
(The MathWorks Inc, Natick, MA, USA) and SPSS 
(Version 15.0 for Windows, Chicago, IL). 
 Results 
 Patients characteristics 
 To assess the power of clinical parameters for the 
































































































































































  Prediction of residual disease in NSCLC  1035prognostic factors were collected before treatment 
and correlated with metabolic response after 
treatment. A total of 101 NSCLC patients were 
included in this analysis, of which 56 (55%) patients 
showed persistent residual FDG uptake on the post-
radiotherapy CT-PET scan and 45 (45%) patients 
had a complete metabolic response (CMR) indi-
cating no residual FDG uptake within the tumor 
post-radiotherapy. Patient, tumor and treatment 
characteristics for both groups are listed in Table I. 
The median follow-up duration was 23.9 months 
(range: 3.8 – 55.5 months). The patients with residual 
active areas post-treatment had a signifi cantly worse 
survival (median survival: 13.4 months) compared to 
patients with a complete metabolic response (median 
survival not reached) (Figure 1; 95% CI, 38.9 – 49.8 
months, p  0.0001). The hazard ratio for death for 
patients with residual areas compared to individuals 
without was 3.701 (95% confi dence interval: 1.92 to 
7.13; p  0.0001 by the log-rank test, two-sided). 
 Univariate analysis 
 To assess the association between patient, tumor and 
treatment characteristics with post-radiotherapy out-
come, a univariate analysis was performed. The area 
under the ROC curve of a univariate model for each 
parameter was estimated. These results are summa-
rized in Table I. The volume of the primary tumor 
(GTV primary ), maximum FDG uptake and OTT had 
the highest predictive power, while other commonly 
used predictors such as FEV 1 , WHO-performance 
status or clinical stage showed a low predictive ability. 
GTV primary was signifi cantly higher for patients with 
residual areas than for patients with a complete meta-
bolic response (103 cm 3   126.13 cm 3 vs. 48.3 cm 3 
  55.5 cm 3 , p   0.008). Similarly, the maximum FDG 
uptake on the pre-RT scan was signifi cantly higher for 
patients with residual disease compared to patients 
with a complete metabolic response (10.5   5 vs. 7.7 
  5.2, p   0.007). The overall treatment time (OTT) 
was longer for patients with a complete metabolic 
response in comparison with patients with residual 
disease (27   6 days vs. 24   5 days, p   0.013). 
 Kaplan-Meier survival curves for subgroups 
determined by the median for selected variables 
are shown in Figure 2. Survival was signifi cantly 
higher for patients with a tumor volume smaller than 
the median (GTV primary  46.6 cm 
3 ) (p  0.001). In 
patients with a SUV max higher than the median 
(SUV max   8.4) in the pre-treatment scan, survival 
was signifi cantly shorter, compared to patients with 
a SUV max lower than the median (p  0.040). Sig-
nifi cant differences in survival were also observed for 
OTT, with a more prolonged survival for patients 
with a treatment time longer than the median of 25  Table I. Patient characteristics and their association with post-RT 
outcome in univariate analysis. Comparison of groups with 
residual disease and with complete metabolic response . Abbreviations: TTD   Total tumor dose; OTT   Overall Treat ment 
Time; SUV max   Standardized Uptake Value; EQD 2, T   Equivalent 
radiation dose at 2 Gy corrected for time; FEV 1   Forced expiratory 
volume in 1 s; SCC   Squamous cell carcinoma; NOS   Not specifi ed 
otherwise; WHO-PS   World Health Organization-performance 
status; PLNS   Positive lymph node stations. 
 ∗ Comparison between residual disease group vs. complete metabolic 
response group for variables. The Mann-Whitney U test was used for 
continuous variables and the Chi-square test for categorical variables. 
1036  E. R. Velazquez et al. days (p  0.042). Survival differences in patients 
stratifi ed according to TNM stage, were statistically 
not signifi cant (p  0.266). The same result was 
obtained for age. Older patients did not have differ-
ent survival compared to younger patients (p  0.998). 
Higher equivalent radiation dose was associated with 
better survival, however the difference was not sta-
tistically signifi cant (p  0.056). 
 Multivariate analysis 
 For the multivariate analysis, all the available 
variables were subjected to a combinatorial feature 
selection procedure. The combination with the 
highest AUC assessed by the leave-one-out cross 
validation approach was selected for the multivari-
ate model. The variables included in the fi nal multi-
variate p-SVM model were GTV primary , maximum 
standardized FDG uptake, OTT and equivalent dose 
corrected for treatment time (EQD 2, T ). Addition of 
other parameters to this model did not improve its 
performance. The area under the curve of the fi nal 
predictive model was 0.71 (95% CI, 0.65 – 0.76; 
Figure 3). The variables included in the multivariate 
model showed also a signifi cant asso ciation with the 
post-radiotherapy outcome in univariate analysis. 
 Discussion 
 In this study we investigated the relationship of clin-
ical parameters, including demographic, tumor and 
treatment characteristics, with metabolic response 
post-treatment. Our primary endpoint was defi ned 
as residual metabolic disease on a post-treatment 
PET-CT scan. Previous studies have shown that patients with residual metabolically active areas after 
treatment have a poorer prognosis compared with 
patients without [10,15,16]. In agreement with these 
studies, also our results showed that patients with 
residual disease had a signifi cantly worse survival 
(p  0.0001), compared to patients with a complete 
metabolic response, thus supporting the importance 
of our primary endpoint as surrogate for survival. 
 Previous studies examined the value of pre-
treatment FDG-PET alone to determine treatment 
response after radiotherapy [17] and chemotherapy 
[18]. In our study, we explored not only the prog-
nostic capability of FDG-PET but also the addi-
tional value of other clinico-pathological prognostic 
factors. Some of them, i.e. age, gender, tumor size, 
WHO performance status have been included in 
predictive models for survival in NSCLC patients 
[19 – 21]. In a retrospective study with a large patient 
population of NSCLC patients (stage I and II) 
which received resection with curative intent, 
Agarwal et al., reported that age and gender, tumor 
volume and type of surgery were important for the 
prediction of survival [22]. However, we did not fi nd 
a signifi cant association between age and metabolic 
response. Similarly, other studies have shown a rela-
tion between female gender and a favorable outcome 
[23]. We did not fi nd a signifi cant difference based 
on gender between responders and non-responders. 
 WHO performance status and FEV 1 , have been 
cited as predictors of survival [19,21], in which worse 
performance status and impaired lung function 
measurements are associated with shorter survival. 
We could not identify an association between these 
parameters and the post-treatment outcome. Although 
the tumor-node-metastasis (TNM) staging system is 
an important tool to estimate prognosis and choose 
the best treatment modality, several studies have 
reported that TNM has a poor predictive capability 
for survival in NSCLC patients [24]. In our cohort, 
the majority of patients were diagnosed with stage 
IIIA (22%) and IIIB (61%) disease. Therefore, stage 
was not a good predictor for residual disease, as 
differences in stage between the responding and the 
non-responding groups were not observed. Great 
interest has been given to the use of FDG-PET as a 
tool for tumor detection, staging and particularly for 
response assessment after radical radiotherapy or 
chemo-radiation [25,26]. The maximum FDG uptake 
in the primary tumor measured on a pre-treatment 
scan has consistently been shown as an important 
prognostic factor for survival in NSCLC [15,18,25]. 
Our results showed that patients with residual meta-
bolically active areas had a signifi cantly higher FDG 
uptake on the pre-treatment scan, compared to 
patients with a complete metabolic response. A high 
pre-treatment FDG uptake within the primary tumor  Figure 1. Kaplan-Meier estimates of overall survival of patients 
with residual metabolically active areas and with complete 
metabolic response on the post-radiotherapy PET-CT scan. 
Patients with residual metabolically active areas had signifi cantly 
worse survival (p   0.0001). 
  Prediction of residual disease in NSCLC  1037was also signifi cantly associated with worse survival 
(p  0.040). Furthermore, the SUV max showed a good 
predictive capability in univariate analysis. 
 Tumor volume also emerged as one of the most 
important predictors of residual disease. Our results 
are consistent with recently published studies, 
which have identifi ed tumor size as an important 
prognostic factor of survival [27]. Here we con-
fi rmed the predictive capability of tumor size in 
assessment of metabolic response. This might 
indicate that specially for larger tumors, an effective 
dose could not be reached due to the dose con-
straints of the current protocol. The total tumor load 
(GTV primary   GTV nodal ) showed a strong associa-
tion with the post-treatment outcome (Table I). This 
association is due to the primary tumor volume, 
and perhaps enhanced by the addition of secondary 
volumes, however GTV nodal alone did not show a 
predictive capability. A similar result was obtained 
for the number of positive lymph node stations on a 
pre-treatment PET-CT scan. Although the number 
of PLNSs is an important risk and staging factor 
for non-surgical patients [28], and has been included  Figure 2. Survival among patients with advanced NSCLC for selected variables. For continuous variables, the cut-off value to stratify the 
patients was defi ned at the variable median. Shown are Kaplan-Meier curves for GTV primary , SUV max , OTT, EQD 2, T , TNM stage and age. 
In panel E, patients with stage I and II were grouped together due to the small number of cases. Stage IV (1 patient) was grouped with 
Stage IIIB.  Figure 3. Area under the ROC curve assessed by the leave-
one-out method for the multivariate model consisting on 
GTV primary , SUV max , OTT and EQD 2, T. A classifier with 
sensitivity of 1 and (1-specificity) of 0, point (0, 1) in graph, 
is ideal. 
1038  E. R. Velazquez et al. in multivariate models for survival in NSCLC, we 
did not fi nd an added prognostic value for residual 
disease, perhaps because the outcome was defi ned 
in the primary tumor. 
 Despite an overall difference of two days, overall 
treatment time was signifi cantly higher for patients 
with complete metabolic response in comparison 
with patients with residual disease. OTT was also 
signifi cantly associated with the outcome in univari-
ate analysis. It is generally accepted that a short 
treatment time should be chosen, to minimize the 
effect of accelerated repopulation [29]. The fact that 
we observe a longer treatment time in patients with 
a positive outcome is because those patients received 
a higher dose. Higher total treatment dose has been 
associated with improved local tumor control and 
better survival [27,30]. In the present study, the 
prescribed total dose was not different for patients 
with a complete response compared to patients with 
residual disease (p  0.809). 
 Several predictive models of survival have been 
published for NSCLC patients, reporting different 
values of the area under the ROC as performance 
measurement, ranging from 0.65 to 0.86. These mod-
els were developed on populations that underwent 
different treatment modalities such as surgery [31], 
chemotherapy [28], radiotherapy or a combination 
[32] and consisted of patients with different tumor 
and patient characteristics. Thus, application of those 
models to different scenarios is still subject of research. 
Here we presented a multivariate model for predic-
tion of residual disease. The fi nal model consisted on 
tumor volume, overall treatment time, SUV max and 
equivalent dose corrected for treatment time. This 
model yielded an AUC of 0.71 (95% CI, 0.65 – 0.76). 
This may have clinical relevance for patients identi-
fi ed at risk of treatment failure that may benefi t from 
additional therapy. We were not able to analyze poten-
tial prognostic variables such as molecular markers or 
imaging surrogates [33 – 35] that may improve the 
ability of the presented model to predict the post-
treatment failure. The lack of an external cohort to 
validate the presented model and confi rm our results 
is an important limitation to our study. Our results 
may require validation according to the treatment 
modality to avoid possible confounding effects associ-
ated with multiple treatment modalities. 
 In conclusion, our results demonstrated that 
patients who do not respond to radiotherapy can be 
identifi ed early in the course of their treatment. To our 
knowledge, this is the fi rst study that examines differ-
ent clinico-pathological predictors of residual disease. 
We identifi ed important prognostic factors of residual 
disease and developed a multivariate model that iden-
tifi ed patients at risk of treatment failure. Further-
more, we confi rmed the validity of residual disease as a surrogate of survival. Our results could assist clini-
cians in the treatment decision-making process and in 
stratifi cation of patients for clinical trials. 
 Declaration of interest: The authors report no 
confl icts of interest. The authors alone are respon-
sible for the content and writing of the paper. 
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